Oral Antiplatelet Efficacy of the Platelet GPIIb/IIIa Antagonist, DMP754 in Non-Human Primates - Receptor binding affinity & specificity

Author： Mousa S.A.   Bozarth J.   Youssef A.   Levine B.  

Publisher： Elsevier

ISSN： 0049-3848

Source： Thrombosis Research, Vol.89, Iss.5, 1998-03, pp. : 217-225

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Intranasal Antiplatelet/ Antithrombotic Efficacy of a Novel Platelet GPIIB/IIIA Receptor Antagonist DMP755 - a model for in vivo evaluation of antithrombotic agents

By Mousa S.A.   Mu D.-X.   Hussain M.A.  

Thrombosis Research, Vol. 92, Iss. 3, 1998-11 ,pp. : 115-124

Elsevier

Access to resources Recommend Favorite

Platelet GPIIb/IIIa Receptor Antagonists in Human Ischemic Brain Disease

By  

Current Vascular Pharmacology, Vol. 6, Iss. 1, 2008-01 ,pp. : 29-36

Bentham Science Publishers

Access to resources Recommend Favorite

The anti-platelet and anti-thrombotic effects of FK633, a peptide-mimetic GPIIb/IIIa antagonist

By Aoki T.   Cox D.   Senzaki K.   Seki J.   Tanaka A.   Takasugi H.   Motoyama Y.  

Thrombosis Research, Vol. 81, Iss. 4, 1996-02 ,pp. : 439-450

Elsevier

Access to resources Recommend Favorite

Bleeding Risk of Tirofiban, a Nonpeptide GPIIb/IIIa Platelet Receptor Antagonist in Progressive Stroke: An Open Pilot Study

By  

Cerebrovascular Diseases, Vol. 12, Iss. 4, 2001-11 ,pp. : 308-312

Karger

Access to resources Recommend Favorite

Differential effect of the GPIIb/IIIa antagonist orbofiban on human platelet aggregate formation in vitro

By Racanelli A.L.   Gibbs S.K.   Zondlo S.C.   Seiffert D.A.   Friedman S.M.   Feuerstein G.Z.  

Thrombosis Research, Vol. 110, Iss. 2, 2003-05 ,pp. : 99-105

Elsevier

Access to resources Recommend Favorite